

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 2, 2015**

**PACIRA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35060**  
(Commission  
File Number)

**51-0619477**  
(IRS Employer  
Identification No.)

**5 Sylvan Way, Suite 300, Parsippany, New Jersey 07054**  
(Address of principal executive offices) (Zip Code)

**(973) 254-3560**  
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 2, 2015, Pacira Pharmaceuticals, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders at the Company’s corporate headquarters in Parsippany, New Jersey, at which the Company’s stockholders voted on, and approved, the following proposals:

Proposal No. 1 — Election of three Class I directors to hold office until the 2018 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

<b>Nominee:</b>	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Laura Brege	25,148,577	2,703,160	5,270,606
Mark A. Kronenfeld	26,686,306	1,165,431	5,270,606
Dennis L. Winger	27,763,019	88,718	5,270,606

Proposal No. 2 — Ratification of the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.

<b>For</b>	<b>Against</b>	<b>Abstain</b>
33,054,850	41,601	25,892

Proposal No. 3 — Advisory vote to approve the compensation of the Company’s named executive officers.

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
27,579,771	214,828	57,138	5,270,606

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PACIRA PHARMACEUTICALS, INC.

Date: June 3, 2015

By: /s/ James Scibetta

James Scibetta  
Senior Vice President, Chief Financial Officer  
and Head of Technical Operations